Concerns regarding the safety of the new anticoagulant Xarelto have not been dispelled. Trials carried out with the drug have resulted in a number of fatalities. Dubious practices are also being used to market the product. There are justified fears that a high-risk, over-expensive product with no additional therapeutic benefit is being forced onto the market.
=> British Medical Journal investigation casts doubt over Xarelto trial
=> Countermotion to Bayer Shareholder Meeting: Xarelto under Fire
=> Xarelto: BAYER pays compensation in China
=> Public Citizen: Use of Anti-Clotting Drug Should Not Be Expanded to Prevent Strokes
=> Journalist Ruhi Kandhari from Delhi speaking in BAYER ASM on rivaroxaban trials in India
=> Xarelto: Trial-related deaths in India
=> Safety Concerns with Blood Thinner Xarelto
=> FDA staff fears over bleeding risk of Bayer/J&Js rivaroxaban